XOMA (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average of $20.97

XOMA Co. (NASDAQ:XOMA)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $20.97 and traded as high as $25.40. XOMA shares last traded at $23.69, with a volume of 9,526 shares.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on XOMA shares. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price target on shares of XOMA in a report on Wednesday, May 1st. Leerink Partnrs reaffirmed an “outperform” rating on shares of XOMA in a research report on Monday, April 29th. Finally, SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an “outperform” rating and a $40.00 price target for the company.

XOMA Price Performance

The stock has a market capitalization of $275.75 million, a PE ratio of -5.86 and a beta of 0.57. The company has a debt-to-equity ratio of 1.34, a current ratio of 8.68 and a quick ratio of 8.68. The stock’s fifty day moving average is $25.12 and its 200-day moving average is $20.97.

XOMA (NASDAQ:XOMA) last posted its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The firm had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million. As a group, equities analysts predict that XOMA Co. will post -2.11 earnings per share for the current fiscal year.

Institutional Trading of XOMA

A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets increased its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,543 shares of the biotechnology company’s stock after buying an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.